TLR4 ligands augment antigen-specific CD8+ T lymphocyte responses elicited by a viral vaccine vector. 2010

Elizabeth G Rhee, and R Phelps Kelley, and Isha Agarwal, and Diana M Lynch, and Annalena La Porte, and Nathaniel L Simmons, and Sarah L Clark, and Dan H Barouch
Division of Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.

Toll-like receptor (TLR) ligands are critical activators of innate immunity and are being developed as vaccine adjuvants. However, their utility in conjunction with viral vector-based vaccines remains unclear. In this study, we evaluated the impact of a variety of TLR ligands on antigen-specific CD8(+) T lymphocyte responses elicited by a recombinant adenovirus serotype 26 (rAd26) vector expressing simian immunodeficiency virus Gag in mice. The TLR3 ligand poly(I:C) suppressed Gag-specific cellular immune responses, whereas the TLR4 ligands lipopolysaccharide and monophosphoryl lipid A substantially augmented the magnitude and functionality of these responses by a MyD88- and TRIF-dependent mechanism. These data demonstrate that TLR ligands can modulate the immunogenicity of viral vaccine vectors both positively and negatively. Moreover, these findings suggest the potential utility of TLR4 ligands as adjuvants for rAd vector-based vaccines.

UI MeSH Term Description Entries
D008024 Ligands A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) Ligand
D008070 Lipopolysaccharides Lipid-containing polysaccharides which are endotoxins and important group-specific antigens. They are often derived from the cell wall of gram-negative bacteria and induce immunoglobulin secretion. The lipopolysaccharide molecule consists of three parts: LIPID A, core polysaccharide, and O-specific chains (O ANTIGENS). When derived from Escherichia coli, lipopolysaccharides serve as polyclonal B-cell mitogens commonly used in laboratory immunology. (From Dorland, 28th ed) Lipopolysaccharide,Lipoglycans
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D011070 Poly I-C Interferon inducer consisting of a synthetic, mismatched double-stranded RNA. The polymer is made of one strand each of polyinosinic acid and polycytidylic acid. Poly(I-C),Poly(rI).Poly(rC),Polyinosinic-Polycytidylic Acid,Polyinosinic-Polycytidylic Acid (High MW),Polyriboinosinic-Polyribocytidylic Acid,Polyribose Inosin-Cytidil,Inosin-Cytidil, Polyribose,Poly I C,Polyinosinic Polycytidylic Acid,Polyriboinosinic Polyribocytidylic Acid,Polyribose Inosin Cytidil
D005822 Genetic Vectors DNA molecules capable of autonomous replication within a host cell and into which other DNA sequences can be inserted and thus amplified. Many are derived from PLASMIDS; BACTERIOPHAGES; or VIRUSES. They are used for transporting foreign genes into recipient cells. Genetic vectors possess a functional replicator site and contain GENETIC MARKERS to facilitate their selective recognition. Cloning Vectors,Shuttle Vectors,Vectors, Genetic,Cloning Vector,Genetic Vector,Shuttle Vector,Vector, Cloning,Vector, Genetic,Vector, Shuttle,Vectors, Cloning,Vectors, Shuttle
D000256 Adenoviridae A family of non-enveloped viruses infecting mammals (MASTADENOVIRUS) and birds (AVIADENOVIRUS) or both (ATADENOVIRUS). Infections may be asymptomatic or result in a variety of diseases. Adenoviruses,Ichtadenovirus,Adenovirus,Ichtadenoviruses
D000276 Adjuvants, Immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014614 Vaccines, Synthetic Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified. Antigens, Synthetic,Chemical Vaccine,Chemical Vaccines,Immunogens, Synthetic,Molecular Vaccine,Molecular Vaccines,Recombinant Vaccine,Semisynthetic Vaccine,Semisynthetic Vaccines,Synthetic Antigen,Synthetic Vaccine,Synthetic Vaccines,Vaccines, Recombinant,Synthetic Antigens,Synthetic Immunogens,Vaccines, Chemical,Vaccines, Molecular,Vaccines, Semisynthetic,Antigen, Synthetic,Recombinant Vaccines,Vaccine, Chemical,Vaccine, Molecular,Vaccine, Recombinant,Vaccine, Semisynthetic,Vaccine, Synthetic
D014765 Viral Vaccines Suspensions of attenuated or killed viruses administered for the prevention or treatment of infectious viral disease. Viral Vaccine,Vaccine, Viral,Vaccines, Viral

Related Publications

Elizabeth G Rhee, and R Phelps Kelley, and Isha Agarwal, and Diana M Lynch, and Annalena La Porte, and Nathaniel L Simmons, and Sarah L Clark, and Dan H Barouch
November 2023, Current opinion in HIV and AIDS,
Elizabeth G Rhee, and R Phelps Kelley, and Isha Agarwal, and Diana M Lynch, and Annalena La Porte, and Nathaniel L Simmons, and Sarah L Clark, and Dan H Barouch
May 2000, The Journal of experimental medicine,
Elizabeth G Rhee, and R Phelps Kelley, and Isha Agarwal, and Diana M Lynch, and Annalena La Porte, and Nathaniel L Simmons, and Sarah L Clark, and Dan H Barouch
April 2004, European journal of immunology,
Elizabeth G Rhee, and R Phelps Kelley, and Isha Agarwal, and Diana M Lynch, and Annalena La Porte, and Nathaniel L Simmons, and Sarah L Clark, and Dan H Barouch
September 2011, Cold Spring Harbor perspectives in medicine,
Elizabeth G Rhee, and R Phelps Kelley, and Isha Agarwal, and Diana M Lynch, and Annalena La Porte, and Nathaniel L Simmons, and Sarah L Clark, and Dan H Barouch
February 2002, Journal of immunology (Baltimore, Md. : 1950),
Elizabeth G Rhee, and R Phelps Kelley, and Isha Agarwal, and Diana M Lynch, and Annalena La Porte, and Nathaniel L Simmons, and Sarah L Clark, and Dan H Barouch
December 2006, Journal of virology,
Elizabeth G Rhee, and R Phelps Kelley, and Isha Agarwal, and Diana M Lynch, and Annalena La Porte, and Nathaniel L Simmons, and Sarah L Clark, and Dan H Barouch
June 2003, British journal of haematology,
Elizabeth G Rhee, and R Phelps Kelley, and Isha Agarwal, and Diana M Lynch, and Annalena La Porte, and Nathaniel L Simmons, and Sarah L Clark, and Dan H Barouch
January 1998, Developments in biological standardization,
Elizabeth G Rhee, and R Phelps Kelley, and Isha Agarwal, and Diana M Lynch, and Annalena La Porte, and Nathaniel L Simmons, and Sarah L Clark, and Dan H Barouch
April 2010, Vaccine,
Elizabeth G Rhee, and R Phelps Kelley, and Isha Agarwal, and Diana M Lynch, and Annalena La Porte, and Nathaniel L Simmons, and Sarah L Clark, and Dan H Barouch
October 2019, Cellular immunology,
Copied contents to your clipboard!